This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments (EDs).
This article was originally published by HCPLive®. It has been lightly edited.
Around half of commercially insured children younger than 2 years with acute bronchiolitis had a follow-up interaction within a week of emergency department (ED) discharge, but their follow-ups were not linked to a decrease in ED revisits, according to a study published in JAMA Network Open.1
These new findings and more resulted from a recent retrospective study examining the rates of follow-ups with children in the United States with this lung condition. The study investigators noted that while there is anecdotal evidence that postdischarge follow-up is the norm for many physicians working in EDs, national norms are not established and there are questions about the value of follow-ups.2
The new research was led by Daniel J. Shapiro, MD, MPH, from the Division of Pediatric Emergency Medicine at the University of California, San Francisco.1
“Our objectives were to describe the frequency of postdischarge follow-up visits in a national cohort of ED encounters for bronchiolitis and to assess whether follow-up was associated with decreased hospital reutilization or increased treatment with nonrecommended medications,” Shapiro and colleagues wrote.
Background and Findings
The investigators used a retrospective cohort trial design, assessing electronic health records of pediatric patients who had commercial insurance who were aged 2 or younger. The children who were used as study subjects had been given a diagnosis of acute bronchiolitis between 2018 and 2021.
The study implemented data that the team drew from the MarketScan Commercial Claims and Encounters databases; these databases maintain insurance claims data of over 30 million individuals in the United States.
The investigators excluded subjects who had complex chronic conditions from their analysis, and informed consent was not necessary due to the use of unidentified data. With regard to the primary outcome of interest, the research team looked at the occurrences of follow-up meetings in primary care within 7 days after discharge from EDs.
The team’s secondary outcomes included ED revisits that did not involve subsequent hospitalization. They also recorded hospitalizations and the dispensation of medications that were not recommended by national guidelines, including corticosteroids, albuterol, and antibiotics.
The investigators looked into potential links between follow-up visits and later hospital reutilizations, using multivariable Cox proportional hazard models. The team’s models considered follow-up meetings to be time-varying exposures, and they adjusted for several variables. These variables included age, region, year, sex, weekend discharge, previous outpatient and ED visit history, prior outpatient visits for bronchiolitis that occurred recently, and diagnostic and treatment procedures done at the time of index ED visits.
Overall, of the total 28,338 ED discharges the investigators observed involving 27,000 unique subjects, the team found that 63.3% were younger than 1 year, and 58.8% were male. They concluded that there were recorded follow-up visits within 7 days, for 47.6% of the total discharges.
Over the study period, the proportion of discharges with follow-ups decreased from 48.9% in 2018 to 43.4% in 2021. Various demographic and clinical factors were found to be associated with follow-up visits.
Within a week after discharge, the investigators noted, 17.6% of the total discharges led to an ED revisit. The team also found that 5.2% of these cases resulted in later hospitalizations.
The team also noted that follow-up meetings were not shown to be linked to ED revisits (adjusted HR [aHR], 1.09; 95% CI, 0.93-1.27). They did find that they were positively associated with later hospitalization (aHR, 1.41; 95% CI, 1.20-1.65).
Additionally, the investigators found that prescriptions for corticosteroids, albuterol, and antibiotics were filled more commonly by children that had follow-ups. Specifically, among children attending these follow-ups, the investigators reported that 5.4% filled prescriptions for corticosteroids, 12.2% for albuterol, and 18.5% for antibiotics.
“Given that follow-up visits are common, vary in frequency according to visit characteristics, have uncertain benefits, may result in overtreatment, and carry costs to families and the health care system, prospective investigation is warranted to determine which children with bronchiolitis may benefit from routine follow-up,” they wrote.
References
1. Shapiro DJ, Bourgeois FT, Fine AM, et al. National patterns of outpatient follow-up visits after emergency care for acute bronchiolitis. JAMA Netw Open. 2023;6(10):e2340082. doi:10.1001/jamanetworkopen.2023.40082
2. Coon ER, Destino LA, Greene TH, Vukin E, Stoddard G, Schroeder AR. Comparison of as-needed and scheduled posthospitalization follow-up for children hospitalized for bronchiolitis: the Bronchiolitis Follow-up Intervention Trial (BeneFIT) randomized clinical trial. JAMA Pediatr. 2020;174(9):e201937. doi:10.1001/jamapediatrics.2020.1937
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More